Global Women's Health Market 2014-2018: Key Vendors are Actavis, Bayer, Eli Lilly and Co, Merck & Co and Pfizer

News provided by

Research and Markets

28 Oct, 2014, 19:22 GMT

DUBLIN, Oct. 28, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men.

Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health.

The analysts forecast the Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Women's Health market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment:

  • Postmenopausal Osteoporosis (Drugs)
  • Hormonal Contraceptives (Drugs and Devices)
  • Menopause (Drugs)
  • Infertility (Drugs)
  • Endometriosis (Drugs)
  • Polycystic Ovary Syndrome (Drugs)

The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical.

Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix and all next-generation GnRH antagonists for women's and men's health.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Application

08. Global Postmenopausal Osteoporosis Market

09. Global Hormonal Contraceptives Market

10. Global Menopause Market

11. Global Infertility Market

12. Global Endometriosis Market

13. Global Polycystic Ovary Syndrome Market

14. Geographical Segmentation

15. Buying Criteria

16. Market Growth Drivers

17. Drivers and their Impact

18. Market Challenges

19. Impact of Drivers and Challenges

20. Market Trends

21. Trends and their Impact

22. Vendor Landscape

23. Key Vendor Analysis

24. Other Reports in this Series

Companies Mentioned:

  • ANI
  • AbbVie
  • Actavis plc
  • Adamis
  • Agile Therapeutics
  • Amgen
  • Apothecus
  • AstraZeneca plc
  • Bayer AG
  • Blairex Laboratories
  • Catalysis SL
  • Crinetics
  • Dexa Medica Group
  • EffRx
  • Eli Lilly and Co.
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • HLL Lifecare Ltd.
  • Janssen
  • Ligand
  • Lipocine
  • Lupin
  • Mayer Laboratories
  • Medicines 360
  • Merck & Co.
  • Mylan Laboratories
  • Neurocrine Biosciences
  • Pantarhei Bioscience BV
  • Pfizer
  • Teva

For more information visit http://www.researchandmarkets.com/research/k9lp65/global_womens

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com